c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Se han encontrado 144 productos de "c-Met / HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Boditrectinib
CAS:Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.Fórmula:C23H24F2N6OForma y color:SolidPeso molecular:438.47Glesatinib hydrochloride
CAS:Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H28ClF2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:656.16Vabametkib
CAS:Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.Fórmula:C29H34N12OForma y color:SolidPeso molecular:566.66c-Met-IN-16
CAS:c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .Fórmula:C21H17F2N9OForma y color:SolidPeso molecular:449.42Mifanertinib
CAS:Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Fórmula:C21H19ClF3N5O2Forma y color:SolidPeso molecular:465.86Axl-IN-8
CAS:Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).Fórmula:C31H29FN6O3Forma y color:SolidPeso molecular:552.6c-Met-IN-11
CAS:c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).Fórmula:C30H20F2N4O3Forma y color:SolidPeso molecular:522.5LCRF-0004
CAS:LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.Fórmula:C28H18F4N6O2SForma y color:SolidPeso molecular:578.54AC-386
CAS:AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.Fórmula:C35H34FN5O6Forma y color:SolidPeso molecular:639.67SAR125844
CAS:SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Fórmula:C25H23FN8O2S2Pureza:98.73%Forma y color:SolidPeso molecular:550.63Ref: TM-T5467
1mg34,00€5mg74,00€10mg110,00€25mg215,00€50mg344,00€100mg557,00€200mg790,00€1mL*10mM (DMSO)92,00€Mifanertinib dimaleate
CAS:Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .Fórmula:C29H27ClF3N5O10Forma y color:SolidPeso molecular:698Tyrosine kinase-IN-4
CAS:Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].Fórmula:C23H21N3O3Forma y color:SolidPeso molecular:387.43Glesatinib
CAS:Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H27F2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:619.7Terevalefim
CAS:Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.Fórmula:C9H8N2SPureza:99.8%Forma y color:SolidPeso molecular:176.24Ref: TM-T37596
1mg52,00€5mg113,00€10mg200,00€25mg349,00€50mg510,00€100mg712,00€500mg1.459,00€1mL*10mM (DMSO)113,00€(rel)-Tivantinib
CAS:(rel)-Tivantinib is a potent, highly selective inhibitor of the receptor tyrosine kinase c-MET and has additional novel targets, GSK3α and GSK3β, that areFórmula:C23H19N3O2Forma y color:SolidPeso molecular:369.42Tyrosine kinase-IN-6
CAS:Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].Fórmula:C37H31F2N5O5SPureza:98%Forma y color:SolidPeso molecular:695.73SOMG-833 HCl
CAS:SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.Fórmula:C22H22F3N5O2Pureza:98%Forma y color:SolidPeso molecular:445.44c-met-IN-1
CAS:c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.Fórmula:C35H37FN6O5Pureza:98%Forma y color:SolidPeso molecular:640.7SOMCL-863
CAS:SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo.
Fórmula:C23H24F3N5O3Pureza:98%Forma y color:SolidPeso molecular:475.46(3S,4S)-Tivantinib
CAS:(3S,4S)-Tivantinib, a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET, targets GSK3α and GSK3β—two novel enzymes implicated in theFórmula:C23H19N3O2Forma y color:SolidPeso molecular:369.42Entacapone acid
CAS:Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).Fórmula:C10H6N2O6Pureza:98.86%Forma y color:SolidPeso molecular:250.16OSI-296
CAS:OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.Fórmula:C21H19Cl2FN4O3Pureza:98%Forma y color:SolidPeso molecular:465.3MET kinase-IN-3
CAS:MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.Fórmula:C25H16ClF2N5O2Forma y color:SolidPeso molecular:491.88Emzeltrectinib
CAS:Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Fórmula:C17H15F3N6OForma y color:SolidPeso molecular:376.34Resencatinib
CAS:Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Fórmula:C30H29N7O3Forma y color:SolidPeso molecular:535.6met-kinase-in-2
CAS:MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.Fórmula:C33H27FN4O4Forma y color:SolidPeso molecular:562.59BPI-9016M
CAS:BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.Fórmula:C25H18F2N4O3Forma y color:SolidPeso molecular:460.43MK-2461
CAS:MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with anFórmula:C24H25N5O5SPureza:95.41% - 99.67%Forma y color:SolidPeso molecular:495.55Ref: TM-T6094
1mg50,00€5mg114,00€10mg177,00€25mg344,00€50mg523,00€100mg798,00€200mg1.071,00€1mL*10mM (DMSO)127,00€Zongertinib
CAS:Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (Fórmula:C29H29N9O2Pureza:98.24%Forma y color:SolidPeso molecular:535.6Ref: TM-T69534
1mg66,00€5mg145,00€10mg222,00€25mg371,00€50mg522,00€100mg708,00€1mL*10mM (DMSO)170,00€EGFR-IN-8
CAS:EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC
Fórmula:C32H23ClF3N7O4Pureza:99.51%Forma y color:SolidPeso molecular:662.02KRC-00715
CAS:KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.Fórmula:C25H25F3N8O3Forma y color:SolidPeso molecular:542.51c-Met-IN-26
CAS:c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Fórmula:C24H19F2N9Forma y color:SolidPeso molecular:471.46SJF 8240
CAS:c-MET degrader with foretinib linked to VHL ligand; reduces c-MET in 6h, hampers AKT, halts GTL16 cells (IC50=66.7nM), acts on exon-14-less c-MET.
Fórmula:C58H65F2N7O11SForma y color:SolidPeso molecular:1106.25c-Met-IN-2
CAS:c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Fórmula:C24H21FN10OPureza:98%Forma y color:SolidPeso molecular:484.49Juvenile hormone B 3 (mixture of diastereomers)
CAS:Juvenile hormone B 3 (Juvenile hormone III bisepoxide) (mixture of diastereomers) is a sesquiterpenoid hormone. It can be isolated from the corpora allata (CA) of higher dipteran insects such as fruit flies and Drosophila melanogaster. This hormone exhibits anti-metamorphic activity and induces the expression of Kr-h1 by directly interacting with juvenile hormone (JH) receptors (Met and Gce). Juvenile hormone B 3 (mixture of diastereomers) is applicable in insect lethality studies.Fórmula:C16H26O4Forma y color:SolidPeso molecular:282.38KIN-8741
CAS:KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.Fórmula:C26H23F2N3O6Forma y color:SolidPeso molecular:511.47D6808
D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.Fórmula:C30H25F3N6O2Forma y color:SolidPeso molecular:558.55BMS-748730
CAS:BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.Fórmula:C22H26ClN7O3SForma y color:SolidPeso molecular:504.01c-Met ligand-Linker Conjugate 2
CAS:c-Met ligand-Linker Conjugate 2 is a synthetic target protein ligand-linker complex used in the synthesis of PROTACs, such as PROTACc-Met degrader-6. PROTACc-Met degrader-6 is a c-Met PROTAC degrader that exhibits antitumor activity.Fórmula:C28H27N7O2Forma y color:SolidPeso molecular:493.563-Fluoro-desmethyl-cabozantinib-C3-O-C3-PEG-acid
CAS:3-Fluoro-desmethyl-cabozantinib-C3-O-C3-PEG-acid is a target protein ligand-linker conjugate combining a c-Met ligand with a PROTAC linker to recruit E3 ligase. It is applicable for synthesizing PROTACs, such as SJF-8240.Fórmula:C36H37F2N3O9Forma y color:SolidPeso molecular:693.69Zurletrectinib
CAS:Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.Fórmula:C19H19F2N7O2Forma y color:SolidPeso molecular:415.4PF-07265807
CAS:PF-07265807 is a highly efficient dual inhibitor of TAM and c-Met, IC50=6.1 nM, 13.2 nM, and 21.6 nM for AXL/MER/TOYRO3, cancer.Fórmula:C29H27F2N7O5Forma y color:SolidPeso molecular:591.57Tyrosine kinase inhibitor
CAS:Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Fórmula:C31H31FN6O5Pureza:98%Forma y color:SolidPeso molecular:586.61Canlitinib
CAS:Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.
Fórmula:C33H31F2N3O7Pureza:98%Forma y color:SolidPeso molecular:619.61
